Navigation Links
Sanovas Awarded Patent for Abrading Balloon Catheter for Extravasated Drug Delivery
Date:12/3/2013

SAUSALITO, Calif., Dec. 3, 2013 /PRNewswire/ -- Sanovas, Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies announced today that the United States Patent and Trademark Office issued patent # 8,597,239 for the company's Abrading Balloon Catheter for Extravasated Drug Delivery.

The Abrading Balloon Catheter for Extravasated Drug Delivery is a multi-lumen balloon catheter that features abrasive outer surfaces upon the substrate of the balloons that are intended to abrade tissue and stimulate cellular function to optimize the osmotic uptake of therapeutic agents into target tissues. The device temporarily occludes a specific region to create a localized treatment chamber for the focal and/or circumferential delivery of various types of therapeutic agents to treat a variety of disease states via the company's patented methods of extravasated drug delivery.

"We believe clinicians will appreciate the broad utility of this asset," related Sanovas CEO, Larry Gerrans. "This will be an intelligent and effective device intended to significantly improve localized, precision therapies. It is analogous to the Swiss Army Knife of Drug Delivery Catheters."

The technology measures and modulates the volumetric pressure gradients of therapeutic agent(s) within the treatment chamber(s) to perfuse the agent(s) across the tissue membrane enabling controlled delivery of the agents directly to target tissues. The system affords clinicians substantial procedural control, including the ability to select the therapeutic agent(s) of their choice and to continuously circulate, irrigate, abrade, extravasate and evacuate the treatment site while mitigating the systemic release of the agent.

"This patent is a significant cornerstone to the company's NanoVas™ portfolio of Interventional Drug Delivery Solutions," said Gerrans. "These tools are vital to the continued growth and promise of Personalized Medicine."  

Sanovas expects to commercialize the technology in coordination with its various partners to meet unmet clinical needs in Pulmonology, Cardiology, Neurology and Uro-Gynecology.

About Sanovas

Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body; enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways.

Contact for Sanovas:

Steve Goldsmith
Vice President Marketing
sgoldsmith@sanovas.com
(415) 729- 9391 ext. 1023


'/>"/>
SOURCE Sanovas, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanovas Launches Next Generation Surgical Imaging Technology
2. Sanovas Fills Corporate Bench with Industry Veterans In Clinical, Regulatory and Finance
3. Sanovas Forms Scientific Advisory Board to Support Development of Lung Cancer Technology
4. WPPS GO Team Awarded Tums and Eno Global Account by GlaxoSmithKline
5. T1D Exchange Awarded $2.8M Grant by JDRF to Study Metformin and Type 1 Diabetes
6. NanoBio Awarded Up To $10 Million In NIH Funding To Develop A Pandemic Influenza Vaccine
7. Pfenex Inc. awarded a subcontract by Leidos to develop a scalable cGMP production process for a second key malaria antigen
8. AMRI Awarded Development and Manufacture Contract from the UK Government
9. Numotion Awarded Best Complex Rehab Provider
10. Isis Pharmaceuticals Stanley Crooke Awarded Corporate Forums Director of the Year
11. Access Pharmaceuticals Awarded Second European Patent for MuGard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)...  Zymo Research Corp. announced today the final ... that help researchers obtain the most accurate and ... rapid growth of the study of microbiomes has ... methods to improve the reproducibility and quality of ... every step of the measurement process including collection ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... 27, 2016 , ... This campaign aims to provide a path to improved ... can control and change. , As nearly 795,000 Americans suffering from a new or ... States. Plus, with an estimated 129,000 of these people dying from stroke, it’s become ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses ... human interest stories, courtesy of leaders in the nursing and health care industry. ... from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... hosted members and suppliers for its inaugural Member Conference at the Paris Hotel ... of elevating the operational health of America’s healthcare providers. , The conference was ...
Breaking Medicine News(10 mins):